• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Guardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    11/18/24 4:44:01 PM ET
    $GHSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GHSI alert in real time by email
    false --12-31 0001642375 0001642375 2024-11-14 2024-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 14, 2024

     

    GUARDION HEALTH SCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38861   47-4428421

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    2925 Richmond Avenue, Suite 1200

    Houston, Texas 77098

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (800) 873-5141

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

     

    Securities registered pursuant to Section 12(b) of the Act: None.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On November 14, 2024, the Board of Directors (the “Board”) of Guardion Health Sciences, Inc. (the “Company”) approved Amendment No. 2 (the “Amendment”) to the Second Amended and Restated Bylaws of the Company (the “Bylaws”), effective immediately. The Amendment reduced the number of directors of the Company from a range of three to seven directors to a range of one to two directors. The exact number of directors within the range is set, from time to time, by the Board. On November 14, 2024, the Board fixed the number of directors at two.

     

    Effective as of November 14, 2024, Michaela Griggs and Don Gagliano resigned from the Board of the Company, in recognition of the reduced number of directors of the Company pursuant to the Amendment. The resignations of each of Ms. Griggs and Mr. Gagliano was not the result of any disagreement between either Ms. Griggs or Mr. Gagliano and the Company, its management, the Board or any committee of the Board, or with respect to any matter relating to the Company’s operations, policies or practices. As there are no disagreements as contemplated by Item 5.02(a) of Form 8-K, the Company is disclosing this information pursuant to Item 5.02(b) of Form 8-K. The remaining members of the Board are Robert N. Weingarten and Mark Goldstone.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    The information set forth in Item 5.02 related to the Amendment is incorporated herein by reference.

     

    This description is only a summary of the changes made to the Bylaws pursuant to the Amendment and is qualified in its entirety by reference to the Amendment, which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Exhibit
    3.1   Amendment No. 2 to Second Amended and Restated Bylaws.
    104   Cover Page Interactive Data File (embedded within the XBRL document)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 18, 2024 GUARDION HEALTH SCIENCES, INC.
       (Registrant)
         
      By: /s/ Katie Cox
      Name: Katie Cox
      Title: Chief Accounting Officer

     

     

     

    Get the next $GHSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GHSI

    DatePrice TargetRatingAnalyst
    3/8/2022$0.60Buy
    Maxim Group
    More analyst ratings

    $GHSI
    Financials

    Live finance-specific insights

    See more
    • Guardion Health Sciences Announces Filing of Certificate of Dissolution

      HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per

      10/30/24 5:37:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

      HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re

      8/21/24 4:05:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024

      Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t

      8/13/24 4:35:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Guardion Health Sciences with a new price target

      Maxim Group initiated coverage of Guardion Health Sciences with a rating of Buy and set a new price target of $0.60

      3/8/22 8:54:48 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      11/8/24 3:46:07 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Guardion Health Sciences Inc.

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      8/28/24 4:06:01 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Guardion Health Sciences Inc. (Amendment)

      SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)

      2/6/24 10:19:56 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardion Health Sciences Announces Filing of Certificate of Dissolution

      HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per

      10/30/24 5:37:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO

      Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas

      10/1/24 9:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Declares Cash Dividend of $5.00 Per Share of Common Stock

      HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re

      8/21/24 4:05:00 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Radoff Bradley Louis sold $1,626,419 worth of shares (115,540 units at $14.08), decreasing direct ownership by 48% to 112,414 units (SEC Form 4)

      4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      8/28/24 4:11:39 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Great Point Capital Llc claimed ownership of 159,652 units of Guardion Health Sciences (SEC Form 3)

      3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      4/3/24 12:54:58 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Cox Katharine Joan

      3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)

      8/7/23 8:47:26 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    SEC Filings

    See more
    • Guardion Health Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)

      11/18/24 4:44:01 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)

      10/31/24 5:07:48 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25 filed by Guardion Health Sciences Inc.

      25 - Guardion Health Sciences, Inc. (0001642375) (Filer)

      10/11/24 3:45:50 PM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GHSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Guardion Health Sciences Announces Adoption of Plan of Dissolution and Liquidation; Appointment of Interim President and CEO

      Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas

      10/1/24 9:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall as President and Chief Executive Officer

      HOUSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that Janet ("Jan") Hall has been appointed as the Company's new President and Chief Executive Officer. Ms. Hall is assuming these executive positions from Bret Scholtes, who has served in those positions since January 6, 2021. Mr. Scholtes is resigning effective June 9, 2023, and is also concurrently resigning from the Board of Directors of the Company. Ms.

      5/30/23 8:00:00 AM ET
      $GHSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of Directors

      AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of DirectorsWICHITA, KS / ACCESSWIRE / December 7, 2022 / AgEagle Aerial Systems Inc. (NYSE:UAVS) ("AgEagle" or the "Company"), an industry-leading provider of full stack flight hardware, sensors and software for commercial and government/defense use, today announced the appointment of Kelly Anderson, CPA as a new independent member of AgEagle's Board of Directors, effective today, December 5, 2022. Anderson will also serve as Chairperson of the Audit Committee and as a member of both the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective December 5, 2022."We are very pleased to we

      12/7/22 8:30:00 AM ET
      $FAF
      $FSR
      $GHSI
      $TOMZ
      Specialty Insurers
      Finance
      Auto Manufacturing
      Consumer Discretionary